TC Biopharm (Holdings) PLC announced that it has received MHRA and Research Ethics Committee approvals to initiate gamma-delta T cell therapy clinical trials of OmnImmune® for the treatment of Acute Myeloid Leukemia (AML). OmnImmune® an allogeneic unmodified cell therapy consisting of activated and expanded gamma delta T cells has already received orphan drug designation for…

eTurboNews atik yo se pou abonnés sèlman. Abònman se GRATIS.
Abonnés konekte isit la Klike la a pou w abònman GRATIS

KISA POU RETIRE NAN ATIK SA A:

TC Biopharm (Holdings) PLC te anonse ke li te resevwa apwobasyon MHRA ak Rechèch Etik Komite pou kòmanse esè klinik terapi gamma-delta T selil OmnImmune® pou tretman Lesemi Acute Myeloid (AML).
OmnImmune® an allogeneic unmodified cell therapy consisting of activated and expanded gamma delta T cells has already received orphan drug designation for….
eTurboNews atik yo se pou abonnés sèlman.